# Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

> **NCT02360215** · PHASE3 · COMPLETED · sponsor: **NRG Oncology** · enrollment: 518 (actual)

## Conditions studied

- Cognitive Impairment
- Metastatic Malignant Neoplasm in the Brain
- Solid Neoplasm

## Interventions

- **RADIATION:** Whole brain radiation therapy with hippocampal avoidance
- **DRUG:** Memantine
- **RADIATION:** Whole brain radiation therapy

## Key facts

- **NCT ID:** NCT02360215
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-04-30
- **Final completion:** 2019-08-26
- **Target enrollment:** 518 (ACTUAL)
- **Last updated:** 2025-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02360215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02360215, "Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT02360215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*